BSP:H1OL34 (USA)
Business Description
Hologic Inc
NAICS : 334517
SIC : 3844
250 Campus Drive, Marlborough, MA, USA, 01752
Description
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.84 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | 1.19 | |||||
| Interest Coverage | 20.34 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.35 | |||||
| Beneish M-Score | -3.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 22.8 | |||||
| 3-Year EBITDA Growth Rate | 143.3 | |||||
| 3-Year FCF Growth Rate | 54.1 | |||||
| 3-Year Book Growth Rate | 22.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | -18.74 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -10.44 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.6 | |||||
| 9-Day RSI | 33.15 | |||||
| 14-Day RSI | 36.4 | |||||
| 6-1 Month Momentum % | -11.78 | |||||
| 12-1 Month Momentum % | -7.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.91 | |||||
| Quick Ratio | 3.32 | |||||
| Cash Ratio | 2.37 | |||||
| Days Inventory | 100.23 | |||||
| Days Sales Outstanding | 61.15 | |||||
| Days Payable | 40.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 2.1 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.35 | |||||
| Operating Margin % | 36.47 | |||||
| Net Margin % | 28.93 | |||||
| ROE % | 33.74 | |||||
| ROA % | 16.56 | |||||
| ROIC % | 22.83 | |||||
| ROC (Joel Greenblatt) % | 149.85 | |||||
| ROCE % | 24.8 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.31 | |||||
| Forward PE Ratio | 19.31 | |||||
| PE Ratio without NRI | 12.31 | |||||
| Shiller PE Ratio | 45.07 | |||||
| Price-to-Owner-Earnings | 8.29 | |||||
| PEG Ratio | 0.69 | |||||
| PS Ratio | 3.56 | |||||
| PB Ratio | 3.64 | |||||
| Price-to-Tangible-Book | 66.11 | |||||
| Price-to-Free-Cash-Flow | 8.07 | |||||
| Price-to-Operating-Cash-Flow | 7.68 | |||||
| EV-to-EBIT | 9.59 | |||||
| EV-to-Forward-EBIT | 15.34 | |||||
| EV-to-EBITDA | 7.82 | |||||
| EV-to-Forward-EBITDA | 12.96 | |||||
| EV-to-Revenue | 3.58 | |||||
| EV-to-Forward-Revenue | 4.25 | |||||
| EV-to-FCF | 8.11 | |||||
| Price-to-Projected-FCF | 1.06 | |||||
| Price-to-Median-PS-Value | 0.98 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.5 | |||||
| Price-to-Graham-Number | 6.01 | |||||
| Earnings Yield (Greenblatt) % | 10.43 | |||||
| Forward Rate of Return (Yacktman) % | 25.66 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 27,475.201 | ||
| EPS (TTM) (R$) | 31.285 | ||
| Beta | 0 | ||
| Volatility % | 15.51 | ||
| 14-Day RSI | 36.4 | ||
| 14-Day ATR (R$) | 1.080083 | ||
| 20-Day SMA (R$) | 373.954 | ||
| 12-1 Month Momentum % | -7.4 | ||
| 52-Week Range (R$) | 368.9 - 423 | ||
| Shares Outstanding (Mil) | 249.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hologic Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||